Table 3.
Immunotherapy Options After Checkpoint Inhibitors
| Study | Arms | Line of Therapy | N | Phase |
|---|---|---|---|---|
| BOND2 (NCT02365818) | Oncolytic virus CG0070 in high-grade NMIBC after BCG failure | Second-line | 122 | 3 |
| SPICE (NCT02636036) | Enadenotucirev + PD-1 inhibitor | Second-line | 30 | 1 |
| CANON (NCT02316171) | Coxsackievirus A21 +/− mitomycin C in NMIBC | First-line | 15 | 1 |
| TACTASOM (NCT02239861) | TAA-specific CTLs (adoptive T-cell therapy) | Second-line | 18 | 1 |
| RANGE (NCT02426125) | Docetaxel +/− ramucirumab | Second-line | 524 | 3 |
| CA-ALT-801-01-10 (NCT01326871) | ALT-801 + cisplatin + gemcitabine (phase 1b and phase 2) ALT-801 + gemcitabine (phase 2 only) |
First-line | 90 | 1/2 |
| CA-ALT-801-01-12 (NCT01625260) | Gemcitabine + ALT-801 in NMIBC after BCG | Second-line | 52 | 1/2 |
| B-701-U21 (NCT02401542) | Arm 1: B-701, an anti-FGFR3 antibody, in locally advanced or metastatic bladder cancer Arm 2: Docetaxel +/− B-701 |
Second-line | 211 | 1/2 |
| MK-6018–001 (NCT02346955) | CM-24 (MK-6018) +/− pembrolizumab in selected advanced or recurrent malignancies | Second-line | 196 | 1 |
| GEN702 (NCT02552121) | Tisotumab vedotin (HuMax-TF-ADC) | Second-line in tumors expressing tissue factor | 44 | 1/2 |
| AGS15E-13–1 (NCT01963052) | AGS15E monotherapy in metastatic urothelial cancer | Second-line or later | 45+ | 1/2 |
| ASG-22CE-13–2 (NCT02091999) | ASG-22CE (enfortumab vedotin) in metastatic urothelial cancer and other solid tumors expressing Nectin-4 | Second-line or later | 200 | 2 |
BCG, bacillus Calmette-Guérin; CTL, cytotoxic T lymphocyte; FGFR3, fibroblast growth factor receptor 3; NMIBC, non–muscle-invasive bladder cancer; PD-1, programmed death 1; TAA, tumor-associated antigen.